Drugs / Kinisoquin™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06861088 | Dec 2025 → Oct 2027 expected | pancreatic adenocarcinoma, venous thromboembolism | Quercis Pharma AG | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kinisoquin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06861088 ↗ |
| Route | Oral | “administered orally” NCT06861088 ↗ |